Targeting Root Causes of Obesity and Metabolic Disease with Harith Rajagopalan Fractyl Health TRANSCRIPT
Release Date: 07/08/2026
Using AI to Unify Healthcare HR Systems to Reduce Administrative Burden with Craig Ahrens Worki TRANSCRIPT
Empowered Patient Podcast
Craig Ahrens is the CEO of Worki, a healthcare workforce management platform that aggregates fragmented HR records by unifying disparate data sources and deploying AI agents to streamline workflows. To address anxieties, the focus needs to be on reducing administrative burdens through intelligent scheduling, not on eliminating jobs. Transparency is key for employees in this integration of legacy systems with AI-powered tools, so that healthcare organizations can improve resource allocation, enhance retention, and improve patient care while maintaining human oversight. ...
info_outline
Using AI to Unify Healthcare HR Systems to Reduce Administrative Burden with Craig Ahrens Worki
Empowered Patient Podcast
Craig Ahrens is the CEO of Worki, a healthcare workforce management platform that aggregates fragmented HR records by unifying disparate data sources and deploying AI agents to streamline workflows. To address anxieties, the focus needs to be on reducing administrative burdens through intelligent scheduling, not on eliminating jobs. Transparency is key for employees in this integration of legacy systems with AI-powered tools, so that healthcare organizations can improve resource allocation, enhance retention, and improve patient care while maintaining human oversight. ...
info_outline
Integrated Continuous Data-Driven Care for Severe Mental Illness with Sonia Garcia Amae Health TRANSCRIPT
Empowered Patient Podcast
Sonia Garcia, Co-Founder and Chief Growth Officer at Amae Health, an integrated care company specializing in the treatment of severe mental illness that operates community-oriented clinics to deliver comprehensive psychiatry-led care. They provide continuity of care across multiple acuity levels, recognizing these conditions require long-term management. Amae is also advancing psychiatric care through research and partnerships by deploying wearables for health monitoring and investigating biomarkers and pharmacogenomics to improve treatment outcomes. Sonia explains, "Amae Health is an...
info_outline
Integrated Continuous Data-Driven Care for Severe Mental Illness with Sonia Garcia Amae Health
Empowered Patient Podcast
Sonia Garcia, Co-Founder and Chief Growth Officer at Amae Health, an integrated care company specializing in the treatment of severe mental illness that operates community-oriented clinics to deliver comprehensive psychiatry-led care. They provide continuity of care across multiple acuity levels, recognizing these conditions require long-term management. Amae is also advancing psychiatric care through research and partnerships by deploying wearables for health monitoring and investigating biomarkers and pharmacogenomics to improve treatment outcomes. Sonia explains, "Amae Health is an...
info_outline
Expanding Advanced Lung Transplant Assessment and Utilization with Sarah Lowe XVIVO TRANSCRIPT
Empowered Patient Podcast
Sarah Lowe, Global Clinical Operations Director at XVIVO, develops technologies to preserve, assess, and transport organs for transplantation. With advanced assessment of donor lungs, the mission is to evaluate marginal organs better to address the critical challenge that only 2 out of 10 available lungs are currently accepted for transplant. With their first in-house ex vivo lung perfusion program, the goal is to increase organ utilization and expand access to transplants. Sarah explains, "At XVIVO, our vision really is that nobody should die waiting for a new organ. As a company, we develop...
info_outline
Expanding Advanced Lung Transplant Assessment and Utilization with Sarah Lowe XVIVO
Empowered Patient Podcast
Sarah Lowe, Global Clinical Operations Director at XVIVO, develops technologies to preserve, assess, and transport organs for transplantation. With advanced assessment of donor lungs, the mission is to evaluate marginal organs better to address the critical challenge that only 2 out of 10 available lungs are currently accepted for transplant. With their first in-house ex vivo lung perfusion program, the goal is to increase organ utilization and expand access to transplants. Sarah explains, "At XVIVO, our vision really is that nobody should die waiting for a new organ. As a company, we develop...
info_outline
Platform Targets Root Causes of Disease to Drive Drug Discovery with Vin Singh Bullfrog AI TRANSCRIPT
Empowered Patient Podcast
Vin Singh, Founder, Chairman, and CEO of Bullfrog AI, is applying proprietary AI technology to drug development, with a focus on drug target discovery and phase three clinical trials. The company's platform is derived from the Johns Hopkins University Applied Physics Lab and is designed to pinpoint drug targets, identify the root causes of disease, and match patients to appropriate treatments based on genetic profiles. Bullfrog AI aims to reduce clinical trial timelines, improve success rates, identify more accurate biomarkers, and improve patient outcomes. Vin explains, "We are in the AI...
info_outline
Platform Targets Root Causes of Disease to Drive Drug Discovery with Vin Singh Bullfrog AI
Empowered Patient Podcast
Vin Singh, Founder, Chairman, and CEO of Bullfrog AI, is applying proprietary AI technology to drug development, with a focus on drug target discovery and phase three clinical trials. The company's platform is derived from the Johns Hopkins University Applied Physics Lab and is designed to pinpoint drug targets, identify the root causes of disease, and match patients to appropriate treatments based on genetic profiles. Bullfrog AI aims to reduce clinical trial timelines, improve success rates, identify more accurate biomarkers, and improve patient outcomes. Vin explains, "We are in the AI...
info_outline
Addressing Social Drivers of Health to Improve Patient Outcomes with Dr. Greg Carroll ClinNEXUS TRANSCRIPT
Empowered Patient Podcast
Dr. Greg Carroll, emergency physician and Co-Founder and CEO of ClinNEXUS, a data-first healthcare company addressing social drivers of health in underserved communities by breaking down data silos. Integrating clinical information with social, behavioral, and environmental factors and using AI to augment human care coordinators enables them to identify patient needs proactively and provide personalized support. The model emphasizes building trust through in-person engagement while leveraging digital tools to enhance the care manager's ability to process complex data and deliver...
info_outline
Addressing Social Drivers of Health to Improve Patient Outcomes with Dr. Greg Carroll ClinNEXUS
Empowered Patient Podcast
Dr. Greg Carroll, emergency physician and Co-Founder and CEO of ClinNEXUS, a data-first healthcare company addressing social drivers of health in underserved communities by breaking down data silos. Integrating clinical information with social, behavioral, and environmental factors and using AI to augment human care coordinators enables them to identify patient needs proactively and provide personalized support. The model emphasizes building trust through in-person engagement while leveraging digital tools to enhance the care manager's ability to process complex data and deliver...
info_outlineHarith Rajagopalan, Co-Founder and CEO of Fractyl Health, is developing innovative therapies that target the root causes of obesity and metabolic diseases to achieve durable, long-lasting patient outcomes. Their drug is designed to address post-GLP-1 rebound weight gain by treating the underlying gut damage. Unlike GLP-1 medications that manage symptoms through appetite suppression, the aim is to modify the disease driving the obesity and change the paradigm from a symptomatic treatment to one of disease modification.
Harith explains, "Our focus at Fractyl is all about how to achieve durable results for patients, long-lasting benefits. And the way in which we try to do so is by targeting root causes of obesity and metabolic disease and developing innovative therapies, targeting those root causes that offer the potential for long-lasting benefit for patients."
"I think that GLP-1s have been transformative, as you say, but they have in many ways created an altogether new problem called post-GLP-1 rebound. What we are seeing in the United States right now is that there are a million people a month who are stopping a GLP-1. The more effective GLP-1 was for them in weight and metabolic control, the more rapidly they rebounded to whatever their weight and metabolic control were prior to treatment."
"Whereas what we are doing is with our lead asset, Revita, we are targeting a root cause of obesity in the gut, a region of the gut that becomes damaged by chronic lifetime exposure to high-fat, high-sugar diets that we think is actually driving the obesity in the first place. And so if you can fix the underlying obesity, then we think that you can prevent the rebound that inevitably occurs upon the discontinuation of the medicine."
#FractylHealth #Revita #Rejuva #PopulationHealth #ObesityMedicine #Endocrinology #MetabolicHealth #GLP1 #Gastroenterology #DiabetesCare #GeneTherapy
